BioCentury | Feb 17, 2014
Clinical News

Adult stem cells: Phase II data

...43% with high-dose MPCs, 28% with saline a and 30% with HA (p=0.09 for high-dose MPC group...
BioCentury | Jan 14, 2013
Clinical News

NeoFuse: Phase II data

...30-40% lower estimated blood loss during surgery vs. bone autograft (p<0.05 for the 25 million MPC group...
BioCentury | Jan 28, 2002
Financial News

BioVisioN raises $13.3 million

...in a private round led by Heidelberg Innovation. Other investors included Nextech Venture; IVEC; the MPC Group...
Items per page:
1 - 3 of 3
BioCentury | Feb 17, 2014
Clinical News

Adult stem cells: Phase II data

...43% with high-dose MPCs, 28% with saline a and 30% with HA (p=0.09 for high-dose MPC group...
BioCentury | Jan 14, 2013
Clinical News

NeoFuse: Phase II data

...30-40% lower estimated blood loss during surgery vs. bone autograft (p<0.05 for the 25 million MPC group...
BioCentury | Jan 28, 2002
Financial News

BioVisioN raises $13.3 million

...in a private round led by Heidelberg Innovation. Other investors included Nextech Venture; IVEC; the MPC Group...
Items per page:
1 - 3 of 3